CHINAPLAS
12.3.2019 03:02:11 CET | Business Wire | Press release
The operating environment for most industries became increasingly complex. It is more vital than ever for enterprising businesses to master technological innovation. CHINAPLAS , the Asia’s No. 1 plastics and rubber trade fair, offers an international platform for the release and exchange of advanced new technologies. The show will not only feature more than 3,500 exhibitors but will also organize a series of exciting concurrent events to address those industries’ needs.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190311005047/en/
Plastics Recycling & Circular Economy Conference and Showcase
To foster circular economy is a global consensus to achieve sustainable development. Great potential and bounteous market opportunities arise with it. More and more big brands have announced environmental protection policies of recycling. In 2017, Adidas sold 1 million pairs of running shoes made of ocean plastic waste. How can plastics contribute to sustainable development? Focusing on the concerns of the industry, a “Plastics Recycling & Circular Economy Conference and Showcase ”, will be held with the themes of “Material Science for Sustainability”, “Recycling Technology” and “Environmental Packaging”.
Industry 4.0 Factory of the Future
Industry practitioners can visit the “Industry 4.0 Factory of the Future ” at CHINAPLAS 2019. There will be two themed areas, “Manufacturing Intelligence Control Room” and “Smart Factory”, to demonstrate implementable intelligent solutions. The control room will display operational data recorded at both the on-site machines and a remote smart factory, while the “Smart Factory” will simulate the future manufacturing environment.
Design x Innovation
Recognizing the key role of design in product development, CHINAPLAS 2019 will organize the event “Design x Innovation ”, comprising three parts.
1. CMF Inspiration Walls will display rich resources on Color, Material and Finish.
2. Design Forum will share product experience covering recyclable & sustainable design, low carbon design and CMF applications.
3. CHINAPLAS Designers’ Night .
Tech Talk
By way of open forums, “Tech Talk ” will showcase the hottest product technologies, and focus clearly on cutting-edge solutions. Tech Talk will include 11 major themes, including new energy vehicles, automotive thermoplastic elastomers, 3D printing, Bioplastics, composites, antimicrobial applications, in-mold labeling, precision extrusion, green building solutions, plastics for wearable electronics, long fiber injection molding.
Medical Plastics Connect
“Medical Plastics Connect ” actively promotes medical-grade chemical raw materials and equipment to create an efficient communication platform for medical device, consumables, and pharmaceutical packaging manufacturers. These activities aim to pinpoint for potential buyers the unique medical plastics technologies among the many exhibits active in this sector. "Medical Plastics Connect” activities include “Open Forum”, “Pop-up Kiosk”, “Medical Plastics Guidebook” and “Medical Plastics Guided Tour”.
CHINAPLAS , the Asia’s No. 1 plastics and rubber trade fair, will be held in Guangzhou, PR China, from May 21-24, 2019. An estimated total of over 3,500 exhibitors from all over the world will be presenting to more than 180,000 professional visitors from 150 countries and regions. For more information and pre-registration, please click here .
View source version on businesswire.com: https://www.businesswire.com/news/home/20190311005047/en/
Contact:
Stella Yuen Chinaplas.PR@adsale.com.hk
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom